1. Home
  2. KYNB vs KTTA Comparison

KYNB vs KTTA Comparison

Compare KYNB & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KYNB

Kyntra Bio Inc. Common Stock

N/A

Current Price

$6.74

Market Cap

27.1M

Sector

Health Care

ML Signal

N/A

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.53

Market Cap

23.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KYNB
KTTA
Founded
1993
2020
Country
United States
United States
Employees
34
5
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.1M
23.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KYNB
KTTA
Price
$6.74
$0.53
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
31.1K
445.3K
Earning Date
05-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.32
$0.28
52 Week High
$9.58
$2.06

Technical Indicators

Market Signals
Indicator
KYNB
KTTA
Relative Strength Index (RSI) 49.58 34.80
Support Level $6.58 $0.54
Resistance Level $7.41 $0.76
Average True Range (ATR) 0.30 0.05
MACD 0.01 -0.00
Stochastic Oscillator 22.95 32.63

Price Performance

Historical Comparison
KYNB
KTTA

About KYNB Kyntra Bio Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Share on Social Networks: